TCGA-CN-A49C-01A-11R-A24H-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.510
- OXIDATIVE_PHOSPHORYLATION+0.350
- DNA_REPAIR+0.340
- G2M_CHECKPOINT+0.340
- FATTY_ACID_METABOLISM+0.230
- SPERMATOGENESIS+0.230
- CHOLESTEROL_HOMEOSTASIS+0.170
- GLYCOLYSIS+0.120
- PEROXISOME+0.100
- MYC_TARGETS_V1+0.090
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.550
- ANGIOGENESIS-0.500
- KRAS_SIGNALING_UP-0.380
- MYOGENESIS-0.360
- UV_RESPONSE_DN-0.350
- TNFA_SIGNALING_VIA_NFKB-0.340
- IL6_JAK_STAT3_SIGNALING-0.330
- HEDGEHOG_SIGNALING-0.320
- APICAL_JUNCTION-0.300
- ALLOGRAFT_REJECTION-0.280
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-CN-A6V7-01A-12R-A34R-07 | — | — | 0.875 |
| 2 | SRR2932843 | — | — | 0.849 |
| 3 | f8d9864e-e148-4e60-9d9d-3df2897050cd | — | — | 0.839 |
| 4 | TCGA-P3-A5QF-01A-11R-A28V-07 | — | — | 0.837 |
| 5 | SRR1516065 | — | — | 0.835 |
| 6 | TCGA-MZ-A6I9-01A-11R-A31N-07 | — | — | 0.833 |
| 7 | 556f81a3-4af4-4ecb-9b4d-97ecb7cacd56 | — | — | 0.833 |
| 8 | TCGA-T2-A6X0-01A-11R-A34R-07 | — | — | 0.825 |
| 9 | TCGA-B6-A0RL-01A-11R-A084-07 | — | B | 0.823 |
| 10 | TCGA-E2-A107-01A-11R-A10J-07 | — | B | 0.823 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 17 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.510 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.350 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.340 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.340 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.230 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.230 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.170 | Remibrutinib | — uncovered |
| GLYCOLYSIS | 0.120 | Inavolisib | — uncovered |
| PEROXISOME | 0.100 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.090 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.080 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.070 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.060 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.050 | Temsirolimus | — uncovered |
| MITOTIC_SPINDLE | 0.040 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.030 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.020 | Idelalisib | — uncovered |